These strategies also address immune evasion: TGF-β blockade reprograms immunosuppressive TANs (N2) into anti-tumor N1 phenotypes, enhancing radiotherapy responses [366], while EMILIN1 + CAFs in BC counteract TGF-β to recruit cytotoxic T cells [367]. Here, TGFB1 is linked to breast cancer.